A new diagnosis of venous thromboembolism (VTE) frequently occurs during neoadjuvant or adjuvant chemotherapy for patients being treated for ovarian cancer, according to a study reported by Health Day News.
Researchers conducted a retrospective cohort study involving patients diagnosed with ovarian, fallopian tube, and primary peritoneal cancer and receiving neoadjuvant chemotherapy.
The researchers found that 13 of 125 patients with ovarian cancer undergoing neoadjuvant chemotherapy had a venous thromboembolism as a presenting symptom and were excluded from further analysis. Thirty of the 112 patients at risk (26.8%) experienced a venous thromboembolism.
